呼吸道合胞病毒疫苗（辉瑞大药厂）(RSVpreF) - 药物靶点：RSV F protein_在研适应症：呼吸道合胞病毒肺炎，呼吸道合胞体病毒感染，下呼吸道感染_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名

recombinant respiratory syncytial virus pre-fusion F protein, water for injections(Pfizer)、Respiratory Syncytial Virus Vaccine、PF 06928316

+ [4]

靶点

RSV F protein

作用方式

调节剂

作用机制

Respiratory syncytial virus F protein调节剂(呼吸道合胞病毒F蛋白调节剂)

治疗领域

感染呼吸系统疾病

在研适应症

呼吸道合胞病毒肺炎呼吸道合胞体病毒感染下呼吸道感染+ [4]

非在研适应症

流感病毒感染

原研机构

Pfizer Inc.

在研机构

Pfizer Inc.Pfizer Canada ULC

Pfizer Australia Pty Ltd.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

加拿大 (2023-01-04),

下呼吸道感染

最高研发阶段(中国)临床3期

特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)

登录后查看时间轴

关联

26

项与呼吸道合胞病毒疫苗（辉瑞大药厂）相关的临床试验

NCT06546800

/ Not yet recruitingN/A

SPECIAL INVESTIGATION FOR ABRYSVO INTRAMUSCULAR INJECTION -INVESTIGATION IN INDIVIDUALS AGED 60 YEARS OR OLDER-

This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine）designed to confirm the safety in individuals aged 60 years or older under actual clinical practice in Japan.

开始日期2025-04-30

申办/合作机构

Pfizer Inc.

NCT06866405

/ Not yet recruiting临床3期

A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.

This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.

开始日期2025-04-23

申办/合作机构

Pfizer Inc.

NCT06890416

/ Recruiting临床3期

A PHASE 3, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS ≥50 YEARS OF AGE

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.

开始日期2025-04-04

申办/合作机构

Pfizer Inc.

100 项与呼吸道合胞病毒疫苗（辉瑞大药厂）相关的临床结果

登录后查看更多信息

100 项与呼吸道合胞病毒疫苗（辉瑞大药厂）相关的转化医学

登录后查看更多信息

100 项与呼吸道合胞病毒疫苗（辉瑞大药厂）相关的专利（医药）

登录后查看更多信息

135

项与呼吸道合胞病毒疫苗（辉瑞大药厂）相关的文献（医药）

2025-12-31·Journal of Pharmaceutical Policy and Practice

Knowledge, attitude, and perception regarding the respiratory syncytial virus vaccine among healthcare professionals

Article

作者: Abu Hammour, Khawla ; El-dahiyat, Faris ; Abu-Farha, Rana ; Al-Ashwal, Fahmi Y. ; Abu Hammour, Walid ; Abdel-Jalil, Mariam ; Al Manaseer, Qusai ; Abu Hammour, Adnan M.

Background:

Respiratory syncytial virus (RSV) is a significant respiratory pathogen. Despite vaccine availability, uptake remains low, and healthcare professionals play a key role in promoting immunisation. This study aims to evaluate healthcare providers' knowledge, perceptions and practices regarding the RSV vaccine.

Methods:

A validated survey was distributed to healthcare professionals. The study questionnaire contained sections to assess sociodemographic characteristics, knowledge of RSV and its vaccines, healthcare professionals' perception towards RSV and its vaccines, and their perception towards the potential barriers against RSV vaccination. The last section assesses physicians' previous practice in dealing with RSV infection.

Results:

Over half of the participants (56.6%) had no prior awareness of RSV, though many recognised its potential severity, particularly in vulnerable populations like children and older adults (52.6%). Awareness of FDA-approved RSV vaccines was limited, with only 28.1% of respondents familiar with vaccines intended for older adults. Views on vaccination recommendations for older age groups were divided; 23.7% supported vaccination for those 75 and older, while 31.1% advocated for vaccination in those aged 60-74 at higher risk. Perceived barriers to RSV vaccination were prominent. Most respondents (85.1%) cited concerns about vaccine safety as a key obstacle, and 81.1% identified out-of-pocket costs as a significant barrier. Testing for RSV was infrequent (24.6%), mainly due to a lack of effective treatment. Most participants (96.9%) called for greater awareness and education about RSV vaccines, and 91.2% supported recommending the vaccine if it was available and free.

Conclusion:

This study reveals significant gaps in healthcare professionals' knowledge and practices regarding RSV and its vaccines, with substantial barriers to vaccine adoption. Targeted education, improved diagnostics, and addressing vaccine barriers are essential strategies for improving the healthcare response to RSV.

2025-04-10·Eurosurveillance

Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season

Article

作者: Menegale, Francesco ; Poletti, Piero ; Borriello, Catia ; Tirani, Marcello ; Merler, Stefano ; Odelli, Stefano ; Morani, Federica ; Cereda, Danilo ; Scarioni, Simona ; Vezzosi, Luigi ; Pariani, Elena ; Dorigatti, Ilaria

Background:

Respiratory syncytial virus (RSV) is a leading cause of hospitalisation in children worldwide. Recent regulatory approval of monoclonal antibody (mAb) nirsevimab for infants and the RSVpreF vaccine for pregnant women offers promising approaches to mitigate RSV-associated morbidity.

Aim:

To evaluate potential impacts of routine prophylactic campaigns (mAbs targeting infants or maternal vaccination) introduced in the 2024/25 season on hospitalisations from RSV lower respiratory tract infections in Lombardy, Italy.

Methods:

We used a catalytic model informed by data from pre-COVID-19 pandemic (before 2020) and post-pandemic periods (until 2022) to quantify the number of cases and hospitalisations that could be averted by seasonal nirsevimab administration to infants and RSVpreF maternal vaccination, considering changes in susceptibility caused by reduced RSV circulation during the pandemic.

Results:

As a marked proportion of RSV hospitalisations occurs in infants aged ≤ 1 year, seasonal mAb administration to 80% of newborns (uptake levels observed in Spain) was estimated to avert 50.2% (95% CI: 43.5–55.8) of hospitalisations in the total population. Coverage levels close to those observed for childhood vaccines (95%) could result in an additional average 18% reduction in hospitalisations. Vaccination of 65% of pregnant women, resembling the diphtheria–tetanus–pertussis vaccine coverage in Lombardy for this population, was estimated to avert 30.5% (95% CI: 19.6–39.7) of hospitalisations. At influenza vaccine coverage (12%), less than 8% of hospitalisations could be averted by maternal immunisation.

Conclusion:

Routine nirsevimab administration to infants demonstrates clear potential to reduce RSV-associated hospitalisations. Maternal immunisation can help in achieving high protection in at-risk populations.

2025-04-01·BMJ Open

Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System

Article

作者: Alami, Abdallah ; Mattison, Donald R ; Pérez-Lloret, Santiago

Objectives:

To describe the post-marketing safety profile of respiratory syncytial virus prefusion F (RSVpreF) vaccine among pregnant individuals.

Design:

This study analysed adverse event (AE) reports submitted to the U.S. Food and Drug Administration’s Vaccine Adverse Event Reporting System (VAERS) database following RSVpreF immunisation from 1 September 2023 to 23 February 2024.

Setting:

VAERS, as a national spontaneous vaccine safety surveillance system, provides insights into the safety profile of the RSVpreF vaccine in a real-world setting.

Participants:

Surveillance data included all AE reports submitted to VAERS in pregnant individuals following vaccination.

Exposure:

Receipt of RSVpreF vaccine among pregnant individuals in the USA.

Primary and secondary outcome measures:

Descriptive statistics were used to assess all AE reports with RSVpreF, including frequency, gestational age at vaccination, time to AE onset, reported outcomes and proportion of serious reports. Data mining techniques were employed to identify disproportionate reporting of RSVpreF-event pairs. Reports of preterm births were clinically reviewed.

Results:

VAERS received 77 reports pertaining to RSVpreF vaccination in pregnant individuals, with 42 (54.55%) classified as serious. The most frequently reported non-pregnancy-specific AEs were headache, injection site erythema and injection site pain. For pregnancy-specific AEs, preterm birth was the most frequently reported (12.8%), followed by AE terms such as preterm premature rupture of membranes and caesarean section (each at 3.3%), and cervical dilatation, haemorrhage during pregnancy and uterine contractions during pregnancy (each at 1.4%). Our disproportionality analysis indicated signals for various AEs, particularly preterm birth, indicating that reports of preterm birth in conjunction with RSVpreF vaccination were observed more frequently than statistically expected. Most of the reported preterm births were moderate to late, occurring between 32 and less than 37 weeks of gestation. The median time from immunisation to the onset of preterm birth was 3 days, with two-thirds of cases reported within a week of vaccination.

Conclusions:

The AEs reported to VAERS among pregnant individuals vaccinated with RSVpreF largely aligned with the safety profile observed in prelicensure studies; however, this analysis also highlights the previously observed safety signal for preterm birth. Active surveillance studies focusing on maternal and perinatal outcomes are needed to further evaluate this signal and guide future clinical recommendations.

649

项与呼吸道合胞病毒疫苗（辉瑞大药厂）相关的新闻（医药）

2025-04-17

·研发客

扩大接种人群，辉瑞RSV疫苗获美国CDC积极意见

美国时间4月16日，辉瑞宣布，美国疾病控制与预防中心（CDC）免疫实践咨询委员会（ACIP）投票决定扩大其呼吸道合胞病毒（RSV）疫苗Abrysvo适用人群年龄段的推荐范围，将50至59岁成人纳入推荐接种范围，此前的推荐范围为60至74岁的高危成年人和所有75岁及以上的老年人。事实上，Abrysvo此前获得FDA批准的适用范围更大，包括18岁及以上患严重疾病风险较高的成年人和老年人，以及孕妇（以保护婴儿）。但美国CDC的意见对于疫苗在真实世界中的接种至关重要，因为保险公司必须承保该机构添加到其指南中的疫苗接种，不符合CDC推荐年龄范围的人群接种可能面临自费。据美国CDC统计，美国50至59岁成年人中每年有15000至20000例RSV相关住院病例。患有一种或多种疾病（例如肥胖、心血管疾病、糖尿病、慢阻肺、哮喘以及其它慢性或免疫功能低下疾病）的成年人住院风险最高。辉瑞副总裁、疫苗和抗病毒药物美国医学负责人Alejandro Cane表示：“ACIP扩大RSV疫苗接种人群的推荐年龄范围，意味着该疫苗朝着保护和触达50至59岁患有潜在疾病、会增加患严重RSV疾病风险的人群迈出了重要一步。”目前，更新后的ACIP建议只待美国CDC和卫生与公众服务部（HHS）主任的最终批准，即可生效。总第2399期访问研发客网站，深度报道和每日新闻抢鲜看www.PharmaDJ.com

疫苗临床研究

2025-04-17

·医药魔方

辉瑞站在十字路口

千亿美元级别的GLP-1减重赛道，所有的制药巨头都不愿错失，但辉瑞的美梦率先破碎了。去年夏天，因每日2次口服Danuglipron缺乏竞争力且耐受性差，辉瑞将其舍弃并把最后希望寄托在每日1次口服Danuglipron上。遗憾的是，缓释剂型存在肝毒性隐忧，辉瑞只能选择彻底终止开发Danuglipron。这已是辉瑞在口服GLP-1赛道遭遇的第三次挫败。早在2023年，另一款候选药物Lotiglipron就因安全性问题被迫搁置。GLP-1赛道的研发挫败不过辉瑞业绩增长压力的冰山一角：多款拳头产品专利即将到期、核心业务滞涨、多项关键研发进展不及预期…这家“宇宙大药厂”如今正徘徊在找回增长方向的十字路口。辉瑞并未放弃减重市场辉瑞本可以更早在GLP-1赛道卡住身位。在GLP-1被认定为一种降糖物质之时，辉瑞就投资了持有GLP-1发现专利的初创公司Metabolic Biosystems[1]。但GLP-1的极短半衰期限制了其临床应用价值，辉瑞很快便撤离了。十余年后，辉瑞在几次并购交易（其中包括对惠氏的收购）[2-4]中一度将4款早期GLP-1药物收入囊中，但这些项目都没有引起辉瑞的关注，最后无疾而终。2015年，辉瑞重新加入GLP-1的角逐，通过与Sosei Heptares的合作收获了两款小分子GLP-1R激动剂——PF-07081532（即Lotiglipron）和PF-06954522。前者的结局已经揭晓——因导致受试者转氨酶水平升高被弃置，后者正在糖尿病和肥胖人群中开展I期研究。辉瑞追赶GLP-1热潮的渴望很明显，不仅积极寻求外部合作，还通过内部创新孵化了Danuglipron。只可惜两条路线都栽在了安全性问题上，拖慢了辉瑞进军减肥市场的步伐，使其在已经白热化的GLP-1竞争中可能落后竞争对手数年。尽管如此，辉瑞似乎不打算放弃这一潜力巨大的市场。在宣布终止开发Danuglipron的同时，辉瑞明确表示将“继续开发口服GIPR拮抗剂候选药物（PF-07976016）和其它早期肥胖项目”。就在两个月前的财报电话会议上，辉瑞研发总裁Chris Boshoff还提及过将Danuglipron作为PF-07976016潜在搭档的可能性[5]。随着Danuglipron被埋，辉瑞可能需要重新在外部寻找合适的GLP-1资产，以维持其在减重领域的战略布局。数据不错的口服GLP-1或是多靶点药物可能会进入辉瑞的战略考量范围，拥有II期在研产品的硕迪生物、Terns Pharmaceuticals、Viking Therapeutics等公司的股价已经应声先涨。中后期在研小分子GLP-1R激动剂GLP-1产品的布局竞赛如火如荼，罗氏、默沙东、阿斯利康等制药巨头已经用行动说明了对减肥市场的向往。就连已经在GLP-1领域占据领先地位的诺和诺德，也掷下重金买入联邦制药的GLP-1R/GCGR/GIPR激动剂UBT251。跨国药企GLP-1项目交易数量决胜未来的战役在GLP-1大赛道的接连滑铁卢，意味着辉瑞输掉了托举未来的有力筹码，而更紧迫的是，其他核心牌面的胜率似乎也有限，未来之路还不甚明朗。回顾2024年辉瑞交出的成绩单，全年营收虽然呈现同比7%的增长，保住了全球第一大制药巨头的头衔，但在繁荣的背面，危机一同显现。专利悬崖已逼近眼前。未来三年内，抗凝药阿哌沙班、乳腺癌疗法哌柏西利、前列腺癌药物恩扎卢胺等重磅产品将陆续失去市场独占期，可能造成170-180亿美元的收入损失。事实上，即便还未遭受仿制药的冲击，有很多产品的竞争力已在市场剧变中减弱。例如，哌柏西利的销售额出现下滑，此消彼长间CDK4/6赛道的头牌地位被礼来的阿贝西利夺走。此外，辉瑞疫苗板块的门面产品肺炎球菌疫苗沛儿系列增长停滞；RSV疫苗市场变数频生，致使刚上市第2年的Abrysvo销售额已开始缩水。辉瑞也从未回避专利悬崖的危机，它已未雨绸缪地在2020-2023年间加大了并购力度，以快速吸收外部的潜力产品管线。经过消化整合，重金收购的资产逐渐兑现价值。以430亿美元收购Seagen所获得的多款肿瘤产品在2024年贡献了超32亿美元收入；116亿美元收购Biohaven囊获的偏头痛药物瑞美吉泮带来12.63亿美元的增量收入。辉瑞首席执行官Albert Bourla还有更高的期待，他预计并购产品到2030年将贡献200亿美元的收入。也就是说，这不仅能填平专利悬崖带来的收入缺口，还可能会实现额外的增长。预期往往倾向美好的一面，现实却总是发生偏差。辉瑞上百亿美金重注ADC赛道的雄心已出现一丝裂痕。今年初，收购Seagen而来的B7-H4 ADC药物Felmetatug vedotin被辉瑞终止开发，导致10亿美元的无形资产减值。而在2023年的肿瘤日活动上，辉瑞曾把该药物视为乳腺癌领域的潜在增长驱动力之一。另一款明星产品Vepdegestrant同样被辉瑞寄予厚望，乃是其在PROTAC前沿赛道最倚重的竞争筹码。同类产品的竞速中，头顶潜在FIC光环的Vepdegestrant一直备受瞩目，近期公布的首个III期研究数据却浇灭了一些业内人士的期待，因为 Vepdegestrant未能达到总体意向治疗人群的无进展生存期（PFS）主要终点。不过，Vepdegestrant在ESR1突变患者群体中仍有突围希望。该突变是ER+/HER2-晚期乳腺癌患者发生获得性耐药的常见原因，约有40%的接受二线治疗的患者中存在ESR1突变。基因治疗赛道，辉瑞陷于研发与商业化双双失利的困局中。从杜氏肌营养不良症基因疗法Fordadistrogene movaparvovec的III期败北，到退回A型血友病基因疗法Giroctocogene fitelparvovec的全球权益，再到终止已上市的B型血友病基因疗法Fidanacogene elaparvovec的开发和商业化，辉瑞的基因治疗布局几近全面溃败。应对GLP-1赛道的屡次受挫与更多不确定因素交织的局面，辉瑞需要比以往任何时候都更加务实地制定战略决策。能否在创新效率、临床价值与市场空间之间找到新的平衡点，将决定这个巨头能否持续守住制药业王座。这场决胜未来的战役，或许比想象中更加复杂和艰难。- 上下滑动查看参考资料 - [1]https://www.labiotech.eu/in-depth/pfizer-glp-1-missed-opportunity/[2]https://www.fiercebiotech.com/biotech/press-release-pfizer-to-acquire-biorexis-pharmaceutical[3]https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_covx_to_extend_biotherapeutics_investment[4]https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_wyeth_creating_the_world_s_premier_biopharmaceutical_company[5]https://s28.q4cdn.com/781576035/files/doc_financials/2024/q4/PFE-USQ_Transcript_2025-02-04.pdf推荐阅读Genmab启示录：BD之王如何长成Biopharma？Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

并购财报专利到期

2025-04-17

·BioPharmaDive

CDC panel backs broader use of RSV shots

A panel of advisers to the Centers for Disease Control and Prevention on Wednesday recommended lowering the age at which some people can receive a vaccine for respiratory syncytial virus, but stopped short of advocating for booster shots.Committee members voted nearly unanimously endorse vaccination in adults who are 50 to 59 years of age and at a higher risk of severe RSV-related disease. If adopted by the CDC, that recommendation would expand on the agency's current guidance, which suggests use in all people 75 or older and high-risk adults between 60 and 74 years of age.The CDC isnt bound to follow the advice of its committees, though it typically does.The policy would immediately benefit GSK and Pfizer, both of which have RSV shots approved for people under 60. It could also soon help Moderna, whose vaccine the Food and Drug Administration could clear for use in that age group later this year.However, the recommendation comes at a time of uncertainty for the CDC, whose acting director Susan Monarez hasnt yet been confirmed by Congress. The decision to adopt it, then, could fall on Health and Human Services Secretary and prominent vaccine skeptic Robert F. Kennedy Jr.Additionally, while recommending broader use than before, committee members still didnt endorse vaccinating younger adults or booster shots. In a slide presentation, CDC panelists noted how clinical testing hasnt clearly shown an additional dose can improve protection against disease. Levels of protective antibodies appear to surge higher after revaccination, but not as high as they do after an initial dose.Its unclear how people with weakened immune systems will respond, too, the presentation said.There remains important uncertainty in whether revaccination can restore protection to levels seen after the first dose, and this may be more important when developing a recommendation for younger adults who have longer remaining life expectancy, said Michael Melgar, co-lead of the work group for RSV in adults for the CDCs Advisory Committee on Immunization Practices, or ACIP.Committee members also highlighted the risk of Guillain-Barr syndrome, a rare neurological side effect that was added to the prescribing information for Pfizers Abrysvo and GSKs Arexvy last year.Advisers will discuss revaccination at a meeting in June. In the meantime, the lack of an endorsement for boosters remains a major overhang to the market potential of RSV shots, wrote William Blair analyst Myles Minter in a note to clients Thursday.Shares of Pfizer, GSK and Moderna all dipped slightly on Wednesday. '

疫苗

100 项与呼吸道合胞病毒疫苗（辉瑞大药厂）相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
呼吸道合胞病毒肺炎	欧盟	Pfizer Europe MA EEIG	2023-08-23
呼吸道合胞病毒肺炎	冰岛	Pfizer Europe MA EEIG	2023-08-23
呼吸道合胞病毒肺炎	列支敦士登	Pfizer Europe MA EEIG	2023-08-23
呼吸道合胞病毒肺炎	挪威	Pfizer Europe MA EEIG	2023-08-23
呼吸道合胞体病毒感染	美国	Pfizer Inc.	2023-05-31
下呼吸道感染	加拿大	Pfizer Canada ULC	2023-01-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
带状疱疹	临床3期	美国	Pfizer Inc.	2025-04-04
带状疱疹	临床3期	波多黎各	Pfizer Inc.	2025-04-04
流感病毒感染	临床3期	澳大利亚	Pfizer Inc.	2022-04-13
呼吸道感染	临床3期	美国	Pfizer Inc.	2020-06-17
呼吸道感染	临床3期	日本	Pfizer Inc.	2020-06-17
呼吸道感染	临床3期	阿根廷	Pfizer Inc.	2020-06-17
呼吸道感染	临床3期	澳大利亚	Pfizer Inc.	2020-06-17
呼吸道感染	临床3期	巴西	Pfizer Inc.	2020-06-17
呼吸道感染	临床3期	加拿大	Pfizer Inc.	2020-06-17
呼吸道感染	临床3期	智利	Pfizer Inc.	2020-06-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04424316 (MATISSE, CTgov)	临床3期	呼吸道感染	14,727	RSVpreF (Infant Participants: RSVpreF)	鏇觸鹹簾鑰衊觸觸衊觸 = 築顧鏇願憲壓膚範構齋遞鑰鏇築淵遞廠簾繭襯 (製鏇顧鏇艱襯廠範鬱膚, 廠鑰壓製鏇鹽壓網壓憲 ~ 壓繭觸觸糧憲積遞齋糧) 更多	-	2025-02-11
				placebo+RSVpreF (Infant Participants: Placebo)	鏇觸鹹簾鑰衊觸觸衊觸 = 淵膚衊鬱製淵壓網鏇鹽遞鑰鏇築淵遞廠簾繭襯 (製鏇顧鏇艱襯廠範鬱膚, 淵夢憲鹽窪鑰鑰範顧簾 ~ 鏇淵構鑰網餘淵鏇廠鹽) 更多
NCT05886777 (CTgov)	临床2期	新型冠状病毒感染 \| 肺部感染	1,142	QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV)	廠構鏇遞積構顧憲獵築 = 積網獵餘襯鏇齋遞餘築製製顧餘鹹繭鑰積鑰齋 (鑰襯網艱範遞簾願範構, 構遞艱醖夢淵廠襯遞鑰 ~ 積齋鹹積鬱遞糧鏇艱鹽) 更多	-	2024-12-18
				Placebo+BNT162b2+RSVpreF (Group 2: [RSVpreF+BNT162b2] + Placebo)	廠構鏇遞積構顧憲獵築 = 構鑰窪窪獵構糧鏇簾鹹製製顧餘鹹繭鑰積鑰齋 (鑰襯網艱範遞簾願範構, 鑰築膚鑰壓衊鏇壓齋範 ~ 蓋艱蓋蓋鑰窪製獵獵餘) 更多
NCT05788237 (CTgov)	临床1期	流感病毒感染	508	RSVpreF+qIRV (SSA: Group 1: RSVpreF + qIRV)	糧夢顧選醖憲製鹽淵淵 = 鹽鬱願簾鹹築鬱繭簾憲選範醖齋鹽糧淵鏇憲遞 (築網願醖顧鹹醖願蓋鏇, 繭糧獵選獵廠蓋窪範醖 ~ 淵衊壓衊遞糧襯餘窪獵) 更多	-	2024-11-22
				qIRV (SSA: Group 2: qIRV)	糧夢顧選醖憲製鹽淵淵 = 齋網網淵觸鬱獵糧範憲選範醖齋鹽糧淵鏇憲遞 (築網願醖顧鹹醖願蓋鏇, 遞齋鬱襯鑰襯壓餘膚鏇 ~ 襯遞築獵鹹構壓鏇製製) 更多
NCT05842967 (MONeT, PipelineReview) 人工标引	临床3期	呼吸道合胞体病毒感染	203	ABRYSVO	顧夢構獵遞艱膚獵獵鏇(製願遞願構築鹽齋繭網) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. 糧製艱壓簾廠顧齋願獵 (夢襯襯網網鹽壓蓋願襯 ) 更多	积极	2024-08-12
NCT04785612 (Phase 2a study, CTgov)	临床2期	呼吸道合胞体病毒感染	70	RSVPreF (RSVPreF)	範簾顧選構築顧餘膚蓋(壓選構齋鏇積觸艱繭願) = 廠繭憲鹹餘糧淵獵憲繭憲餘淵壓膚膚夢鹽膚艱 (遞鏇遞繭範鑰鹹構齋餘, 構獵窪艱範獵齋鏇膚繭 ~ 艱獵構製夢齋選繭觸獵) 更多	-	2024-08-07
				Placebo (Placebo)	範簾顧選構築顧餘膚蓋(壓選構齋鏇積觸艱繭願) = 顧艱製顧窪夢糧鬱構醖憲餘淵壓膚膚夢鹽膚艱 (遞鏇遞繭範鑰鹹構齋餘, 築繭糧鏇壓鏇簾衊淵積 ~ 築簾憲選願鏇築獵鏇鬱) 更多
NCT04424316 (MATISSE, Pubmed)	临床3期	呼吸道合胞体病毒感染	-	RSVpreF vaccine	壓鬱網鹹夢襯壓築構膚(醖觸範積廠窪網構憲糧) = 鬱網簾窪簾積鑰構顧襯壓憲鑰簾選窪鹽積範範 (選顧壓顧網襯餘窪艱願 ) 更多	积极	2024-06-08
				bivalent RSVpreF maternal vaccination (Placebo)	壓鬱網鹹夢襯壓築構膚(醖觸範積廠窪網構憲糧) = 齋襯鑰糧積衊積網鬱製壓憲鑰簾選窪鹽積範範 (選顧壓顧網襯餘窪艱願 ) 更多
NCT05842967 (MONeT, Corporate Publications) 人工标引	临床3期	慢性阻塞性肺疾病 \| 哮喘 \| 糖尿病 ... 更多	-	ABRYSVO	膚鬱夢遞遞齋鹽淵選願(襯繭壓糧艱衊築淵壓壓) = Participants demonstrated RSV-A and RSV-B subgroup neutralizing responses non-inferior to the response seen in the Phase 3 (NCT05035212) RENOIR study of ABRYSVO in more than 34,000 adults aged 60 or older where vaccine efficacy was previously demonstrated. 餘夢淵壓糧淵鹹構顧鬱 (糧衊齋糧鹹願積簾積窪 ) 达到更多	积极	2024-04-09
NCT05035212 (RENOIR, Biospace) 人工标引	临床3期	呼吸道合胞体病毒感染	-	ABRYSVO (three or more symptoms)	遞鏇顧糧構餘鬱鏇願觸(衊製醖餘襯夢繭糧鹽遞) = 壓鹹觸鏇餘艱積積鑰夢網簾繭淵繭艱鬱艱選壓 (壓夢鑰願鏇艱選繭糧獵, 51.4 ~ 91.1) 更多	积极	2024-03-29
				ABRYSVO (two or more symptoms)	遞鏇顧糧構餘鬱鏇願觸(衊製醖餘襯夢繭糧鹽遞) = 鏇網鑰繭淵醖觸餘鏇觸網簾繭淵繭艱鬱艱選壓 (壓夢鑰願鏇艱選繭糧獵, 34.7 ~ 70.4) 更多
NCT04424316 (MATISSE, NEWS) 人工标引	N/A	呼吸道合胞体病毒感染	-	Abrysvo (first 90 days after birth)	廠艱範築艱膚壓獵鬱襯(製糧觸廠鬱獵繭蓋淵蓋) = 艱構願鏇廠膚範憲餘構膚選窪簾積築餘醖構製 (壓壓鏇製艱獵窪遞蓋築 )	积极	2023-11-29
				Abrysvo (within 180 days)	廠艱範築艱膚壓獵鬱襯(製糧觸廠鬱獵繭蓋淵蓋) = 簾鑰鹹選夢衊襯獵製艱膚選窪簾積築餘醖構製 (壓壓鏇製艱獵窪遞蓋築 )
NCT05035212 (RENOIR, NEWS) 人工标引	N/A	呼吸道合胞体病毒感染	-	Abrysvo (older adults with two or more symptoms of RSV)	夢餘夢齋簾鏇壓糧獵齋(醖範獵獵艱艱鹽製憲窪) = 蓋遞鹽夢築繭構艱觸廠製構觸製鏇鑰憲壓繭鏇 (簾艱願襯觸醖夢鹹衊醖 )	积极	2023-11-29
				Abrysvo (older adults with two or more symptoms)	夢餘夢齋簾鏇壓糧獵齋(醖範獵獵艱艱鹽製憲窪) = 繭鬱繭顧窪選廠襯選鹹製構觸製鏇鑰憲壓繭鏇 (簾艱願襯觸醖夢鹹衊醖 )